ClinicalTrials.gg
RecruitingNCT07033208Updated Oct 2, 2026

Feasibility of a Wireless Thermal Capsule Endoscopy to Detect Gastrointestinal Thermal Variance

An interventional study of Feasibility to obtain thermal variance measurements using a wireless thermal capsule in Crohn Disease, Inflammatory Bowel Diseases and Healthy, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Oct 2, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Crohn Disease by Massachusetts General Hospital — 7 open to participants now, 8 under way, none of them phase 3. Crohn Disease · Massachusetts General Hospital.

Started
2025
with 1 other
No phase
8 of 14
4 open now
Registered
12th of 14
by date

Among the 14 studies in Crohn Disease by Massachusetts General Hospital, this one is one of 2 that started in 2025, is one of 8 with no phase, and was the 12th registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

7 of the 14 studies in Crohn Disease by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Crohn Disease by Massachusetts General Hospital, or all of them as a file.
02

Study summary

The goal of this research is to learn how a new device called the wireless thermal capsule (WTC) can collect thermal data to help see diseases that happen in the gastrointestinal (GI) tract, such as Crohn's Disease.

Read the detailed description

The purpose of this study is to determine the feasibility of using the wireless thermal capsule (WTC) to collect temperature information from the human GI tract in healthy adult subjects. Participants will be asked to do a standard of care bowel prep with instructions to start the prep three days before their scheduled procedure. Participants may also be asked to fast for several hours and consume a series of laxative prep mixtures. This is a two visit study, during the first study visit, informed consent will be collected. Afterwards, a receiver belt and 8 antennas will be placed on the subject's abdomen by trained study staff. The participant will be asked to swallow the WTC capsule, and will have 10 attempts to try to swallow the capsule. They may be also offered optional swallowing aids such as PillGlide or Chloraseptic to help swallow the capsule. If the participant is not able to swallow the capsule after 10 attempts, the research procedure will be terminated. Once the WTC has been swallowed, the subject will be able to go home and will be asked to complete a Participant Daily Record. A member of the study staff may communicate with the subject every few days until the subject has excreted the capsule in their stool or until 50 hours have passed. The second study visit occurs after 50 hours, the subject will return the receiver belt, and Participant Daily Record. Should the participant experience any new symptoms that could indicate a problem in the GI tract, (abdominal discomfort, blood in stool, nausea), a physician will be consulted. The participant may be asked to consume drugs such as metoclopramide or polyethylene glycol to help move the capsule along in their gut. If the capsule hasn't been passed after 50 hours, the participant may be cleared to return home if they have no other symptoms, and may be asked to self monitor until the capsule has passed. The study team will follow up with the participant until the capsule has passed, and the participant may be asked to provide visual confirmation that the capsule has been successfully passed at home. If passage is not confirmed after 2 weeks, the participant may be asked to return to MGH for medical intervention.

03

Conditions studied

  • Crohn Disease
  • Inflammatory Bowel Diseases
  • Healthy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is 18 -75 years old
  • Participant is considered healthy, with no known illnesses
  • Participant can follow fasting requirements
  • Participant can follow bowel prep instructions
  • Participant can provide

Exclusion criteria

Exclusion Criteria:

  • Participant is older than 75 years of age
  • Participant with current dysphagia or any swallowing disorder
  • Participant with any current condition believed to have an increased risk of capsule retention such as gastrointestinal strictures, intestinal tumors, bowel obstruction, incomplete colonoscopies or fistula
  • Participant with a diagnosis of gastroparesis or small bowel or large bowel dysmotility
  • Participant with a history of inflammatory bowel disease (IBD), intestinal Crohn's disease, chronic constipation, or rectal bleeding
  • Participant with clinical evidence of renal disease, including laboratory abnormalities of renal function within the past 6 months
  • Participant with chronic usage of nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Participants with a known contradiction to metoclopramide
  • Participants with a known to polyethylene glycol
  • Participant with currently suspected or diagnosed with hematochezia, melena, iron deficiency with or without anemia
  • Participant who has had intestinal surgery in the past
  • Participant with a history of congestive heart failure
  • Participant with Type I or Type II Diabetes
  • Participant has a cardiac pacemaker or other implanted electromedical device.
  • Participant expected to undergo MRI examination within 7 days after ingestion of the capsule.
  • Participant has participated in an drug or device research study within 30 days of enrollment that may interfere with the subject's safety or ability to participate in this study
  • Participant with delayed gastric emptying
  • Participant who is pregnant, suspected pregnant, or is actively breast-feeding.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Healthy Volunteers

    25 healthy adult participants with no pre-existing gastrointestinal disorders will be enrolled at MGH

    Device: Feasibility to obtain thermal variance measurements using a wireless thermal capsule

Interventions

  • DeviceFeasibility to obtain thermal variance measurements using a wireless thermal capsule

    A total of 25 healthy participants will be enrolled in this study all consented participants will receive the same intervention.

06

What researchers measure

Primary outcomes

  1. Measurement of Gastrointestinal Temperature Mean Variance in adult study participants as measured by the wireless thermal capsule

    This is a pilot study to demonstrate that the capsule can transmit valid temperature data from within the gastrointestinal tract. Since the study participants are nominally healthy, we anticipate that on a per patient basis, the capsule will detect a core body temperature with a mean variance (σ\^2) of +/- 0.5°C. With a study size of 10 participants, the measured mean variance 95% confidence intervals will be 0.24≤σ\^2≤1.6 °C, which is sufficient to demonstrate that the capsule transmits valid gastrointestinal tract temperature data.

    Time frame: 2 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Apr 2027, 22 months after the start.

Of 290 non-industry interventional studies with no phase under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's planned 22 months is below that.

Counting every sponsor, half of 302 studies reached it within 45 months; a quarter within 21 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2025
First posted
Jun 24, 2025
StartActual
Jun 3, 2025
Primary completionEst.
Apr 30, 2027
CompletionEst.
Apr 30, 2027
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
10→25
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Enrollment 10→25
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07033208
Collaborators
The Leona M. and Harry B. Helmsley Charitable Trust
Responsible party
Guillermo Tearney (Principal Investigator - MD, PhD, FACC, FCAP, FNAI, Massachusetts General Hospital) — Principal investigator
First posted
Jun 24, 2025
Start date
Jun 3, 2025
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Oct 2, 2026

Study contacts

Anita Chung
Contact
tearneylabtrials@partners.org
6177244515
Guillermo Tearney, MD, PhD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion